Last edition
News about "Sun Pharma "
Sun Pharma Presents New Clinical Efficacy and Safety Data in Dermatology at EADV Congress
The company will also share results in two additional posters for deuruxolitinib, which showed clinically meaningful improvement in anxiety and depression among patients taking deuruxolitinib to treat their severe AA (P2022) as well as dose optimization for deuruxolitinib at 8 mg (P2081).
Sun Pharma | 27/09/2024 | By Aishwarya | 152
Sun Pharma and Moebius Medical Receive FTD for MM-II for Treatment of Osteoarthritis Knee Pain
Sun Pharma and Moebius Medical have announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to MM-II (Large Liposomes of DPPC and DMPC) for the treatment of osteoarthritis knee pain.
Sun Pharma | 07/09/2024 | By Aishwarya
Sun Pharma Signs Non-Exclusive Patent Licensing Deal with Takeda for Vonoprazan
Sun Pharma has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceutical Company Ltd. to commercialise Vonoprazan tablets 10 mg, 20 mg in India under the brand name Voltapraz.
Sun Pharma | 24/06/2024 | By Aishwarya | 305
Sun Pharma | 22/08/2023 | By Sudeep Soparkar | 371
IPA Set to Host 8th Global Pharmaceutical Quality Summit, Focusing on 'Patient Centricity - A New Manufacturing and Quality Paradigm
Sun Pharma | 14/06/2023 | By Sudeep Soparkar | 639
Sun Pharma recalls more than 34,000 bottles of generic medication in US
The lot was manufactured at the Mumbai-based drugmaker's Halol-based manufacturing facility in Gujarat that has failed dissolution testing
Sun Pharma | 13/02/2023 | By Sudeep Soparkar | 455
Sun Pharma in agreement with Cosmo Pharma
Announce territory expansion of license and supply agreements for WINLEVI to include Japan, Australia, New Zealand, Brazil, Mexico and Russia
<br />
Sun Pharma | 26/07/2022 | By Sudeep Soparkar | 456
Pharma cos recall products in US due to manufacturing issues
Sun Pharma is recalling the affected lot due to "water leakage" leading to deviation from current good manufacturing practices (cGMP)
Sun Pharma | 25/07/2022 | By Sudeep Soparkar | 374
Sun Pharma Launches RIOMET ER Oral Suspension in the U.S.
Sun Pharmaceutical Industries Ltd. today announced that one of its wholly-owned subsidiaries has launched Riomet ER in the U.S. as an adjunct to diet and exercise to improve glycemic control in patients 10 years of age and older with type 2 diabetes mellitus. Riomet ER was approved by the U.S. Food and Drug Administration (FDA) on August 29, 2019
Sun Pharma | 14/03/2020 | By Darshana | 147
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy